

Neurotech

19 October 2020

New Chairman Appointed

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to advise that experienced biotechnology entrepreneur, Brian Leedman has been appointed Non-executive Chairman effective immediately. Mr Leedman is the founder and former director of a number of ASX listed biotechnology companies that have achieved large returns for shareholders and we are excited to have him join our team following the recent completion of the Company's exclusive worldwide licence to use proprietary cannabis strains for medicinal use in treating autism, epilepsy and ADHD.

Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Non-executive Director of Alcidion Corporation. He is presently the Chairman of NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions. He holds a BEc and an MBA from the University of Western Australia and has over 15 years' experience in the biotechnology sector.

"I am very pleased to be joining the board of Neurotech at a very exciting time for the company," said Mr Leedman. "The newly in-licensed cannabis strains for treating neurological disorders represent tremendous commercial opportunities that match perfectly with the use of our Mente platform for monitoring patients in our forthcoming clinical studies".

Concurrently Mr Peter Griffiths has transitioned from his role as a director and Chief Executive Officer of the Company to Chief Executive Officer of the Company's Maltese subsidiary AAT Research Ltd overseeing the Company's Mente program, and Dr David Cantor has retired from the Board of the Company. The Board thanks Mr Griffiths and Dr Cantor for their service as directors of the Company.

The Company has agreed to seek shareholder approval for a grant of options to Mr Leedman. Upon shareholder approval, 10,000,000 Options (\$0.015, 31 October 2023) and 10,000,000 Options (\$0.02, 31 October 2023) will be issued subject to the vesting condition that Mr Leedman remains a director of the Company until 19 April 2021.

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Brian Leedman
Chairman
+61 41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

Neurotech International Ltd
ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com